Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc (TOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Theriva Biologics Receives FDA Guidance for Phase 3 Study of VCN-01 in Metastatic Pancreatic Adenocarcinoma Quiver Quantitative, Inc. - Thu Dec 5, 5:20PM CST

Theriva Biologics received FDA guidance on VCN-01's Phase 3 study for metastatic pancreatic cancer treatment, optimizing trial design.Quiver AI SummaryTheriva Biologics has announced the outcomes of a...

TOVX : 1.1700 (-1.68%)
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer GlobeNewswire - Thu Dec 5, 7:00AM CST

TOVX : 1.1700 (-1.68%)
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results GlobeNewswire - Tue Nov 12, 7:00AM CST

TOVX : 1.1700 (-1.68%)
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant GlobeNewswire - Thu Oct 31, 3:05PM CDT

TOVX : 1.1700 (-1.68%)
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma GlobeNewswire - Wed Oct 16, 7:00AM CDT

TOVX : 1.1700 (-1.68%)
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients GlobeNewswire - Thu Oct 3, 7:00AM CDT

TOVX : 1.1700 (-1.68%)
Wall Street - shutterstock_2269106477
S&P Futures Tick Lower Ahead of Powell Speech, Chip War Heats Up Barchart - Wed Jun 28, 2023

September S&P 500 futures (ESU23) are trending down -0.15% this morning as a report on potential new restrictions on the export of artificial intelligence chips to China weighed on sentiment, while investors...

ESU23 : 4,491.72s (-0.32%)
MSFT : 437.39 (-3.76%)
AAPL : 248.05 (-2.14%)
AMZN : 220.52 (-4.60%)
META : 597.19 (-3.59%)
DAL : 58.88 (-3.17%)
SNOW : 162.59 (-4.81%)
WBA : 9.70 (-2.71%)
RIDE : 2.20 (+2.33%)
MU : 103.90 (-4.33%)
GIS : 63.91 (-3.06%)
CA.FP : 13.765 (+0.18%)

Barchart Exclusives

2 Dividend Stocks Analysts Love for Fat Yields in 2025 Barchart - Wed Dec 18, 6:30PM CST
These companies have high yields and have strong business models that position them to maintain and potentially increase their dividend payments in 2025. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot